ArticleBMC surgery2026
Distal vs. total pancreatectomy with celiac axis resection in patients with locally advanced/borderline resectable pancreatic carcinoma - a retrospective cohort study.
Article in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDistal pancreatectomy with celiac axis resection (DP-CAR) is an established procedure for the resection of celiac-trunk-infiltrating carcinomas of the pancreatic corpus or cauda. In contrast, total pancreatectomy with celiac axis resection (TP-CAR) remains a controversial procedure, which is sporadically mentioned in the literature. This study aimed to compare perioperative and survival outcomes following TP-CAR with those of the established DP-CAR operation.
methodsBetween January 2010 and December 2023, 17 patients underwent DP-CAR and 8 patients TP-CAR in our institution. Pre-, intra-, postoperative, histopathological and survival data were compared between the two groups.
resultsThe TP-CAR cohort was associated with higher rates of major complications (DP-CAR: 2[12%] vs. TP-CAR: 4[50%], p = 0.037) and stomach ischemia (DP-CAR: 1[5.9%] vs. TP-CAR: 3[37.5%], p = 0.044). Length of stay in the intensive care unit was longer for the TP-CAR group (DP-CAR:1[1-1] vs. TP-CAR:18[8-27] days, p < 0.001). One patient in our study died postoperatively, belonging to the DP-CAR group. Median overall survival (DP-CAR:21[95% CI:16-26] vs. TP-CAR 14[95% CI:11.4-16.6] months, p = 0.355) and disease-free survival (DP-CAR: 12[95% CI:9.2-14.8] vs. TP-CAR: 10.5[5.4-15.6] months, p = 0.659) were higher in the DP-CAR group, without statistically significant difference in the log-rank test.
conclusionsCompared to DP-CAR, TP-CAR was associated with higher morbidity and longer stay in the intensive care unit, while mortality remained low in this cohort. Given the limited sample size and the absence of significant survival differences, TP-CAR may be considered in highly selected patients with good performance status and adequate tumour regression after neoadjuvant chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.